Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Hele, Everaus"'
Autor:
Heikki Kuusanmäki, Aino-Maija Leppä, Petri Pölönen, Mika Kontro, Olli Dufva, Debashish Deb, Bhagwan Yadav, Oscar Brück, Ashwini Kumar, Hele Everaus, Bjørn T. Gjertsen, Merja Heinäniemi, Kimmo Porkka, Satu Mustjoki, Caroline A. Heckman
Publikováno v:
Haematologica, Vol 105, Iss 3 (2020)
Externí odkaz:
https://doaj.org/article/9d9ce60433f4483e96edb2bc4fcd137d
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background Cervical cancer (CC) incidence in Estonia is the third highest in Europe, even though an organised nation-wide screening program has been in place since 2006. The aim of the study was to analyse the incidence and survival of CC in
Externí odkaz:
https://doaj.org/article/7b81900d20be466c86b908990a648e06
Autor:
Wolfgang Willenbacher, Brian Fox, Peter de Nully Brown, Judit Jørgensen, Neus Domper Rubio, Marie-Laure Casadebaig, Richard Greil, Hele Everaus, Ulrich Jäger, Lorenz Trümper, David Cunningham, Oliver Manzke, Thomas Stauffer Larsen, Krish Patel, Justine Dell’Aringa, Nurgul Kilavuz, Grzegorz S. Nowakowski, Nagesh Kalakonda, Robert Manges, Javier Munoz
Publikováno v:
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell’Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell'Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M-L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell'Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M-L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can incre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d8c12cf157023fa610230261b321fc
https://portal.findresearcher.sdu.dk/da/publications/a1eda3b7-edc6-42d6-9940-c2ac96b43009
https://portal.findresearcher.sdu.dk/da/publications/a1eda3b7-edc6-42d6-9940-c2ac96b43009
Autor:
Grzegorz S, Nowakowski, Wolfgang, Willenbacher, Richard, Greil, Thomas S, Larsen, Krish, Patel, Ulrich, Jäger, Robert F, Manges, Lorenz, Trümper, Hele, Everaus, Nagesh, Kalakonda, Peter, Brown, Judit Meszaros, Jørgensen, David, Cunningham, Justine, Dell'Aringa, Brian, Fox, Neus Domper, Rubio, Nurgul, Kilavuz, Marie-Laure, Casadebaig, Oliver, Manzke, Javier, Munoz
Publikováno v:
International journal of hematology. 115(2)
Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can incre
Autor:
Andrija Bogdanovic, Boris Labar, Martin Höglund, Edgar Faber, Hele Everaus, Richard E. Clark, Adriana Colita, Rüdiger Hehlmann, Sonja Heibl, Anna G. Turkina, Ulla Olsson-Strömberg, Francisco Cervantes, Michele Baccarani, Tomasz Sacha, Verena S. Hoffmann, Michael Lauseker, Daniela Zackova, Markus Pfirrmann, Andreas Hochhaus, Laimonas Griskevicius, Perttu Koskenvesa, Susanne Saussele, Irena Preložnik Zupan, Joerg Hasford, Andrey Zaritskey, Gert J. Ossenkoppele, Fausto Castagnetti, Witold Prejzner, François Guilhot, Joelle Guilhot
Publikováno v:
Leukemia
Leukemia, 34(8), 2138-2149. Nature Publishing Group
Leukemia, London : Nature Publishing Group, 2020, vol. 34, no. 8, p. 2138-2149
Pfirrmann, M, Clark, R E, Prejzner, W, Lauseker, M, Baccarani, M, Saussele, S, Guilhot, F, Heibl, S, Hehlmann, R, Faber, E, Turkina, A, Ossenkoppele, G, Höglund, M, Zaritskey, A, Griskevicius, L, Olsson-Strömberg, U, Everaus, H, Koskenvesa, P, Labar, B, Sacha, T, Zackova, D, Cervantes, F, Colita, A, Zupan, I, Bogdanovic, A, Castagnetti, F, Guilhot, J, Hasford, J, Hochhaus, A & Hoffmann, V S 2020, ' The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia ', Leukemia, vol. 34, no. 8, pp. 2138-2149 . https://doi.org/10.1038/s41375-020-0931-9
Leukemia, 34(8), 2138-2149. Nature Publishing Group
Leukemia, London : Nature Publishing Group, 2020, vol. 34, no. 8, p. 2138-2149
Pfirrmann, M, Clark, R E, Prejzner, W, Lauseker, M, Baccarani, M, Saussele, S, Guilhot, F, Heibl, S, Hehlmann, R, Faber, E, Turkina, A, Ossenkoppele, G, Höglund, M, Zaritskey, A, Griskevicius, L, Olsson-Strömberg, U, Everaus, H, Koskenvesa, P, Labar, B, Sacha, T, Zackova, D, Cervantes, F, Colita, A, Zupan, I, Bogdanovic, A, Castagnetti, F, Guilhot, J, Hasford, J, Hochhaus, A & Hoffmann, V S 2020, ' The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia ', Leukemia, vol. 34, no. 8, pp. 2138-2149 . https://doi.org/10.1038/s41375-020-0931-9
Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim wa
Autor:
Nagesh Kalakonda, Robert Manges, David Cunningham, Richard Greil, Jeanna Knoble, Wolfgang Willenbacher, Javier Munoz, Judit Jørgensen, N. Domper Rubio, Thomas Stauffer Larsen, G.S. Nowakowski, Krina K. Patel, Marie-Laure Casadebaig, Ulrich Jäger, Oliver Manzke, Hele Everaus, Corinne Haioun, P. de Nully Brown, Lorenz Trümper
Publikováno v:
Hematological Oncology. 37:132-134
Publikováno v:
Eurasian Journal of Medicine and Oncology.
Publikováno v:
International Journal of Gynecologic Cancer. 27:44-49
ObjectiveThe objective of the study was to examine temporal trends in ovarian cancer (OC) survival in Estonia during 1995 to 2009 in relation to age and stage.Materials and MethodsEstonian Cancer Registry data on all adult cases of primary OC diagnos
Publikováno v:
Food & Function. 7:3815-3824
Despite numerous studies chronic lymphocytic leukemia (CLL) still remains an incurable disease. Therefore, all new compounds and novel strategies which are able to eradicate CLL cells should be considered as valuable clues for a potential future reme
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
BMC Cancer
BMC Cancer
Background Cervical cancer (CC) incidence in Estonia is the third highest in Europe, even though an organised nation-wide screening program has been in place since 2006. The aim of the study was to analyse the incidence and survival of CC in Estonia,